5th Edition Drug Pricing Transparency Congress

Stay on the Pulse of Federal and State Reporting Requirements, Policy Initiatives and Strategic Best Practices for Implementation

In light of recent focus on HHS’s proposal to eliminate rebates, the Senate Finance hearing with Pharma CEOs, and a strong legislative movement towards transparency, there is a heightened focus on drug pricing transparency in the United States. Recent federal and state rulings create lingering questions around legislation and compliance complexities that will impact the market in real-time causing uncertainty.

Join CBI’s 5th Edition Drug Pricing Transparency Congress, to convene with stakeholders to forecast how drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Assess the advancements of legislation made in 2019, collaborate to scenario plan for the future and share best practices for implementation.

Leave a Comment

Your feedback is valuable for us. Your email will not be published.

Please wait...

Please leave these two fields as-is:
5th Edition Drug Pricing Transparency Congress